Olaparib Combo Improves PFS/Responses... - Advanced Prostate...

Advanced Prostate Cancer

22,373 members28,135 posts

Olaparib Combo Improves PFS/Responses in Metastatic CRPC - from ASCO GU2024

Maxone73 profile image
18 Replies

I am not sure, they always mix BTCA 1/2 and ATM, but maybe I can find the data for ATM only...but results are impressive from the report.

cancernetwork.com/view/olap...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
18 Replies
KocoPr profile image
KocoPr

it says it’s for BRCA 1/2 OR ATM

KocoPr profile image
KocoPr

here is what the trial inclusion says. Kind of vague but im sure one can find the exact mutations somewhere.

From clinicaltrials.gov inclusion criteria #3

#Patients with known germline DNA repair defects are eligible without a biopsy. However it will be highly desirable that they undergo a metastatic (or fresh prostate biopsy if there is clear local disease and no other measurable disease site or biopsiable bone lesion) disease biopsy to better define the scope of the DNA repair defects in the current disease context.”

Maxone73 profile image
Maxone73 in reply toKocoPr

yes but there are trials saying that olaparib works greatly on BRCA 1/2, so-so for ATM and basically does nothing to people with no mutation, that's why it's tricky

KocoPr profile image
KocoPr in reply toMaxone73

Ya I tried to get into the rucaparib trial at Wiel Cornell but my RAD50 mutation was label VUS (variable of Unknown Significance) in prostate cancer. it’s a ver very serious mutation in the BRCA pathway and is well known for colorectal cancer and breast cancer.

oh by the way I am so glad i wasn’t excepted at last minute after traveling 4 hours to NYC, going through all the radiation scans bone, cat, etc, and then surrounded by Homeland Security at Penn station because i set off the radiation detectors. Lol

Maxone73 profile image
Maxone73 in reply toKocoPr

I am ATM mutant instead, dammit

MoonRocket profile image
MoonRocket in reply toMaxone73

Correct, your are a ATM Mutant. 😀

Maxone73 profile image
Maxone73 in reply toMoonRocket

And no ATM machine at home!

MoonRocket profile image
MoonRocket in reply toMaxone73

FWIW, me neither. 😒

MoonRocket profile image
MoonRocket in reply toMaxone73

I believe the reason that tissue biopsy is being used instead of liquid biopsy is the high false positive for ATM. I've listened to a few MO discuss the this issue with regards to ATM response to Parp inhibitors. Some, number unknown, ATM participants did not actually have an ATM mutation. Need to read the more detailed reports from this study to see if anything has changed if tissue biopsies are used.

Maxone73 profile image
Maxone73 in reply toMoonRocket

That would be interesting! I had a repeated blood test for this germline mutation, now I have two sisters and one brother that will have to do the genetic test as well.

Maxone73 profile image
Maxone73 in reply toMoonRocket

I know there was a reliability issue with home kits nature.com/articles/gim201838

But I did not know about hospital tests

MoonRocket profile image
MoonRocket in reply toMaxone73

Read this...ancan.org/liquid-biopsy-tes... explains the issue and how to weed out the false positives.

Maxone73 profile image
Maxone73 in reply toMoonRocket

Interesting… I know they used a double blood sample taken from a different arm, taken 15 minutes from each other and done by a different nurse. But I think that was an internal protocol. I must check if they used plasma or whole blood!

MoonRocket profile image
MoonRocket in reply toMaxone73

My ATM was from my prostate tissue post RP, so my ATM mutation started from the beginning, which is pretty rare from what have read. Anyway, I don't think this false positive was understood when olaparib was first approved. I also think this issue is more common for ATM than the others.

Maxone73 profile image
Maxone73 in reply toMoonRocket

I will find out the report to see if the method is specified and its sensitivity! But they told me they will repeat the test anyway.

MoonRocket profile image
MoonRocket in reply toMaxone73

Germline test would be different in that every cell would be impacted. Usually the germline test are saliva based but don't quote me on that. I'm not a genetic counselor.

The liquid biopsies use material that is shed from the cancer although some is not exclusive to the cancer, hence the issue with some liquid biopsies.

MoonRocket profile image
MoonRocket in reply toKocoPr

I won't put my hand on the Bible, but not all Gene mutation are equal, even within the HRR set of genes. I think there are specific mutations within each gene that are significant while others Variants are Unknown, therefore the VUS designation.

Maxone73 profile image
Maxone73

😂

Not what you're looking for?

You may also like...

Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/interim-ana
6357axbz profile image

Docetaxel Improves Survival in Metastatic Hormone-Naïve Prostate Cancer

TAKE-HOME MESSAGE •This report provides long-term survival data from a randomized trial on...
Balsam01 profile image

Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases

Combo Immune herapy showing positive signs for MCRPC. The combo of immunotherapy drugs are what...
Moespy profile image

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

https://www.onclive.com/view/177lu-pnt2002-significantly-improves-rpfs-vs-arpi-in-metastatic-castrat
Maxone73 profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.